The estimated Net Worth of Ron Cohen is at least $11.1 millió dollars as of 16 March 2023. Ron Cohen owns over 20,156 units of Acorda Therapeutics Inc stock worth over $98,840 and over the last 19 years he sold ACOR stock worth over $8,953,680. In addition, he makes $2,039,560 as President, Chief Executive Officer és Director at Acorda Therapeutics Inc.
Ron has made over 49 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 20,156 units of ACOR stock worth $12,497 on 16 March 2023.
The largest trade he's ever made was exercising 289,778 units of Acorda Therapeutics Inc stock on 16 August 2016 worth over $753,423. On average, Ron trades about 19,075 units every 80 days since 2006. As of 16 March 2023 he still owns at least 149,757 units of Acorda Therapeutics Inc stock.
You can see the complete history of Ron Cohen stock trades at the bottom of the page.
Dr. Ron Cohen, M.D., is President, Chief Executive Officer and Director of Acorda Therapeutics, Inc. Dr. Cohen has served as our President and Chief Executive Officer since he founded the Company in 1995. Dr. Cohen previously was a principal in the startup of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen currently serves on the board of directors of VBL Therapeutics. In addition, within the last five years, he previously served on the board of directors of Dyax Corp. Dr. Cohen previously served as Chair of the board of the Biotechnology Innovation Organization (BIO), as Chair of the Emerging Companies Section of the BIO board, and as a Director and Chairman of New York Biotechnology Association (NYBA). He also previously served as a member of the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. In 2010, Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and is an inductee into the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by NYBA as its "The Cure Starts Here" Business Leader of the Year and was named by MM&M and PR Week as one of the top 50 health influencers of 2017.
As the President, Chief Executive Officer és Director of Acorda Therapeutics Inc, the total compensation of Ron Cohen at Acorda Therapeutics Inc is $2,039,560. There are no executives at Acorda Therapeutics Inc getting paid more.
Ron Cohen is 64, he's been the President, Chief Executive Officer és Director of Acorda Therapeutics Inc since . There are 10 older and 7 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith és Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: